PFIZER INC Operating Lease Cost
PFIZER INC (PFE) reported Operating Lease Cost of $498.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-26
- PFIZER INC operating lease, cost for the quarter ending 2019-12-31 was $111.00M.
- PFIZER INC operating lease, cost for the quarter ending 2019-09-29 was $111.00M.
- PFIZER INC operating lease, cost for the quarter ending 2019-06-30 was $100.00M.
- PFIZER INC operating lease, cost for the quarter ending 2019-03-31 was $100.00M.
- PFIZER INC operating lease, cost for fiscal 2025 was $498.00M, a 27.09% decline from fiscal 2024.
- PFIZER INC operating lease, cost for fiscal 2024 was $683.00M, a 20.86% decline from fiscal 2023.
- PFIZER INC operating lease, cost for fiscal 2023 was $863.00M, a 20.87% increase from fiscal 2022.
- PFIZER INC operating lease, cost for fiscal 2022 was $714.00M, a 30.29% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $498.00M 10-K · filed 2026-02-26 | ||||
| 2024-12-31 | $683.00M 10-K · filed 2026-02-26 | ||||
| 2023-12-31 | $863.00M 10-K · filed 2026-02-26 | ||||
| 2022-12-31 | $714.00M 10-K · filed 2025-02-27 | ||||
| 2021-12-31 | $548.00M 10-K · filed 2024-02-22 | ||||
| 2020-12-31 | $432.00M 10-K · filed 2023-02-23 | $433.00M 10-K · filed 2021-02-25 | |||
| 2019-12-31 | $111.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $222.00M derived: sum of 2 quarters · filed 2022-02-24 | $322.00M derived: sum of 3 quarters · filed 2022-02-24 | $421.00M 10-K · filed 2022-02-24 | $416.00M 10-K · filed 2020-02-27 |
| 2019-09-29 | $111.00M 10-Q · filed 2019-11-07 | $211.00M derived: sum of 2 quarters · filed 2019-11-07 | $310.00M 10-Q · filed 2019-11-07 | ||
| 2019-06-30 | $100.00M 10-Q · filed 2019-08-08 | $200.00M 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $100.00M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |